About Maureen Hennessey, PhD, CPCC, CPHQ Senior Vice President, Director of Value Transformation, PRECISIONvalue

This author has not yet filled in any details.
So far Maureen Hennessey, PhD, CPCC, CPHQ Senior Vice President, Director of Value Transformation, PRECISIONvalue has created 4 blog entries.

Ramping Up SDOH Quality Measures within Value-Based Reimbursement Roadmaps

The Centers for Medicare & Medicaid Services (CMS) recognize that health care spending rises as a percent of gross domestic product (GDP) yearly while also underperforming on quality and equity. In this article we will review current and emerging initiatives including new and proposed SDOH quality measures and activities linked to plan and provider payments and incentives, discuss barriers to success, and propose win-win solutions for pharmaceutical companies to advance these initiatives.

2022-09-21T20:37:06+00:00By |

2022 QPP Proposed Quality Measures and Improvement Activities: New Opportunities for Value-Based Alliances and Collaborations

Stay up to date on the changes to the 2022 QPP proposed quality measures and improvement activities with an overview from Maureen Hennessey, as well as suggested landscape analysis and customer partnership opportunities for pharmaceutical manufacturers in the quality and clinical improvement areas.

2021-10-27T22:04:01+00:00By |

CMS Physician Fee Schedule (PFS) Creates More Tailwinds for Telehealth and New Opportunities for Pharma

Telehealth vendors, health systems, and clinicians are seeing opportunities to further expand delivery of reimbursable telehealth services since CMS issued its (CY) 2021 Medicare Physician Fee Scale final rule on December 1, 2020. Precision’s Maureen Hennessey discussing the impact of these expanded opportunities, and how they set the stage for amping up the velocity for telehealth growth.

2021-02-25T16:05:55+00:00By |

MACRA Is Reshaping How Quality Is Rewarded

Maureen Hennessey from our Quality and Population Health Solutions team provides an overview of MACRA, Medicare’s evolution toward value-based clinical reimbursement. Maureen breaks down the separate tracks of participation for providers and highlights some guidelines for demonstrating value that manufacturers will need to demonstrate.

2017-09-27T16:57:01+00:00By |